Trial Profile
A phase I trial of alpha fetoprotein specific autologous genetically modified T-cells in patients with hepatocellular carcinoma
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2016
Price :
$35
*
At a glance
- Drugs Cell therapies (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Adaptimmune
- 08 Aug 2016 According to an Adaptimmune media release, the Investigative New Drug (IND) for this trial is open and the company anticipates initiation in the first half of 2017.
- 25 Apr 2016 New trial record